A multicenter Asian cohort of 216 patients with NSCLC harboring KRAS alterations (ATORG‐005) showed that the patients treated with ICIs had a longer median OS compared to those without ICIs; however, most of their first‐line treatment was chemotherapy, including only 20 patients who received first‐line ICI therapy.30 Here, KRAS is linked to non-small cell lung carcinoma.